A Phase 1 interventional study of BI 1584862 and Itraconazole in Healthy, sponsored by Boehringer Ingelheim. Completed at 1 site in Germany. Open to male participants aged 18 Years to 50 Years, including healthy volunteers. Per ClinicalTrials.gov, last updated 2026-06-03.
Sponsored by Boehringer Ingelheim · Phase 1, Interventional, and Treatment
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
The main objective of this trial is to investigate the effect on the exposure of BI 1584862 in plasma when given as single dose together with multiple doses of itraconazole (Test, T) as compared to BI 1584862 when given alone as oral single dose (Reference, R).
Boehringer Ingelheim is the lead sponsor of 2,305 studies on the registry; 62 are open to participants now.
Of its 169 completed or terminated interventional studies of FDA-regulated products, 123 (73%) have results posted.
Counted across the registry records on this site, refreshed daily.
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
Exclusion Criteria:
Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
A recording of the heart’s electrical activity, taken with stickers on the chest, arms and legs. It takes a few minutes and does not hurt.
Weight in kilograms divided by height in metres squared. Example: 70 kg and 1.75 m gives 70 ÷ (1.75 × 1.75) ≈ 22.9.
What counts as overweight or obesity differs between countries (some use lower cut-offs), so go by the range the study states.
Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.
You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.
Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.
ECG (electrocardiogram)
A recording of the heart’s electrical activity, taken with stickers on the chest, arms and legs. It takes a few minutes and does not hurt.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
BMI (body mass index)
Weight in kilograms divided by height in metres squared. Example: 70 kg and 1.75 m gives 70 ÷ (1.75 × 1.75) ≈ 22.9.
What counts as overweight or obesity differs between countries (some use lower cut-offs), so go by the range the study states.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Informed consent
Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.
You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Clinically significant
Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Reference treatment (R): healthy male subjects were administered one single dose of BI 1584862 as tablets orally with 240 milliliter (mL) of water after an overnight fast of at least 10 hours (h). Test treatment (T): healthy male subjects were administered one single dose of BI 1584862 as tablets orally with 240 mL of water after an overnight fast of at least 10 h. Additionally, subjects were administered one daily dose of 200 milligram (mg) itraconazole as an oral solution after an overnight fast of at least 9 h for several consecutive days. The two administrations of BI 1584862 were separated by a washout period.
Drug: BI 1584862 · Drug: Itraconazole
One dose with 240 mL of water after an overnight fast of at least 10 h
200 mg daily after an overnight fast of at least 9 h for several consecutive days
Area Under the Concentration-time Curve of BI 1584862 in Plasma Over the Time Interval From 0 Extrapolated to Infinity (AUC0-∞)
Area under the concentration-time curve of BI 1584862 in plasma over the time interval from 0 extrapolated to infinity (AUC0-∞) is reported. Geometric least square mean (adjusted geometric mean) and adjusted geometric standard error were calculated using an analysis of variance (ANOVA) model on the logarithmic scale. The pharmacokinetic (PK) endpoints were log-transformed (natural logarithm) prior to fitting the ANOVA model, which included effects accounting for the following sources of variation: 'subjects' was considered as a random effect, 'treatment' as a fixed effect. These quantities were then back-transformed to the original scale.
Time frame: Within 3 to 4 h before and up to 3 days after BI 1584862 administration.
Maximum Measured Concentration of BI 1584862 in Plasma (Cmax)
Maximum measured concentration of BI 1584862 in plasma (Cmax) is reported. Geometric least square mean (adjusted geometric mean) and adjusted geometric standard error were calculated using an ANOVA model on the logarithmic scale. The PK endpoints were log-transformed (natural logarithm) prior to fitting the ANOVA model, which included effects accounting for the following sources of variation: 'subjects' was considered as a random effect, 'treatment' as a fixed effect. These quantities were then back-transformed to the original scale.
Time frame: Within 3 to 4 h before and up to 3 days after BI 1584862 administration.
Area Under the Concentration-time Curve of BI 1584862 in Plasma Over the Time Interval From 0 to the Last Quantifiable Data Point (AUC0-tz)
Area under the concentration-time curve of BI 1584862 in plasma over the time interval from 0 to the last quantifiable data point (AUC0-tz) is reported. Geometric least square mean (adjusted geometric mean) and adjusted geometric standard error were calculated using an ANOVA model on the logarithmic scale. The PK endpoints were log-transformed (natural logarithm) prior to fitting the ANOVA model, which included effects accounting for the following sources of variation: 'subjects' was considered as a random effect, 'treatment' as a fixed effect. These quantities were then back-transformed to the original scale.
Time frame: Within 3 to 4 h before and up to 3 days after BI 1584862 administration.
This was an open-label, two-period, two-treatment, fixed sequence design trial in healthy male subjects to investigate the effect of itraconazole on the pharmacokinetics of BI 1584862. The trial compared the test treatment (T, BI 1584862 given together with itraconazole) to the reference treatment (R, BI 1584862 given alone) using the fixed sequence R-T.
| Milestone | BI 1584862 (R), Then BI 1584862 + Itraconazole (T) |
|---|---|
| Started | 14 |
| Treated | 14 |
| Completed | 14 |
| Not completed | 0 |
| Milestone | BI 1584862 (R), Then BI 1584862 + Itraconazole (T) |
|---|---|
| Started | 14 |
| Treated | 14 |
| Completed | 14 |
| Not completed | 0 |
Area under the concentration-time curve of BI 1584862 in plasma over the time interval from 0 extrapolated to infinity (AUC0-∞) is reported. Geometric least square mean (adjusted geometric mean) and adjusted geometric standard error were calculated using an analysis of variance (ANOVA) model on the logarithmic scale. The pharmacokinetic (PK) endpoints were log-transformed (natural logarithm) prior to fitting the ANOVA model, which included effects accounting for the following sources of variation: 'subjects' was considered as a random effect, 'treatment' as a fixed effect. These quantities were then back-transformed to the original scale.
| hour*nanomole/Liter | BI 1584862 (R) | BI 1584862 + Itraconazole (T) |
|---|---|---|
| Area Under the Concentration-time Curve of BI 1584862 in Plasma Over the Time Interval From 0 Extrapolated to Infinity (AUC0-∞) | 999.27 ± NA | 7981.53 ± NA |
Maximum measured concentration of BI 1584862 in plasma (Cmax) is reported. Geometric least square mean (adjusted geometric mean) and adjusted geometric standard error were calculated using an ANOVA model on the logarithmic scale. The PK endpoints were log-transformed (natural logarithm) prior to fitting the ANOVA model, which included effects accounting for the following sources of variation: 'subjects' was considered as a random effect, 'treatment' as a fixed effect. These quantities were then back-transformed to the original scale.
| nanomole/Liter | BI 1584862 (R) | BI 1584862 + Itraconazole (T) |
|---|---|---|
| Maximum Measured Concentration of BI 1584862 in Plasma (Cmax) | 408.11 ± NA | 801.07 ± NA |
Area under the concentration-time curve of BI 1584862 in plasma over the time interval from 0 to the last quantifiable data point (AUC0-tz) is reported. Geometric least square mean (adjusted geometric mean) and adjusted geometric standard error were calculated using an ANOVA model on the logarithmic scale. The PK endpoints were log-transformed (natural logarithm) prior to fitting the ANOVA model, which included effects accounting for the following sources of variation: 'subjects' was considered as a random effect, 'treatment' as a fixed effect. These quantities were then back-transformed to the original scale.
| hour*nanomole/Liter | BI 1584862 (R) | BI 1584862 + Itraconazole (T) |
|---|---|---|
| Area Under the Concentration-time Curve of BI 1584862 in Plasma Over the Time Interval From 0 to the Last Quantifiable Data Point (AUC0-tz) | 984.30 ± NA | 7825.12 ± NA |
Collected over Adverse events (AEs): from drug administration and/or residual effect period (REP), up to 7 days. Deaths: from drug administration up to 17 days.. Non-serious events are listed at a 5% frequency threshold.
| Group | Deaths | Serious | Other |
|---|---|---|---|
| BI 1584862 (R) | 0/14 (0%) | 0/14 (0%) | 0/14 (0%) |
| Itraconazole Before BI 1584862 (ITZ-1, T) | 0/14 (0%) | 0/14 (0%) | 3/14 (21.4%) |
| Itraconazole + BI 1584862 (ITZ+BI, T) | 0/14 (0%) | 0/14 (0%) | 1/14 (7.1%) |
| Itraconazole + BI 1584862 (ITZ-2, T) | 0/14 (0%) | 0/14 (0%) | 1/14 (7.1%) |
| Event | BI 1584862 (R) | Itraconazole Before BI 1584862 (ITZ-1, T) | Itraconazole + BI 1584862 (ITZ+BI, T) | Itraconazole + BI 1584862 (ITZ-2, T) |
|---|---|---|---|---|
| Abdominal painGastrointestinal disorders | 0/14 | 1/14 | 0/14 | 0/14 |
| PyrexiaGeneral disorders | 0/14 | 1/14 | 0/14 | 0/14 |
| NasopharyngitisInfections and infestations | 0/14 | 0/14 | 0/14 | 1/14 |
| Oral herpesInfections and infestations | 0/14 | 1/14 | 0/14 | 0/14 |
| ArthralgiaMusculoskeletal and connective tissue disorders | 0/14 | 0/14 | 1/14 | 0/14 |
| Back painMusculoskeletal and connective tissue disorders | 0/14 | 1/14 | 0/14 | 0/14 |
Treated set (TS): the treated set included all subjects who were treated with at least 1 dose of trial drug.
| Age, Continuous(Years) | BI 1584862 (R), Then BI 1584862 + Itraconazole (T) |
|---|---|
| Mean | 32.4 ± 6.6 |
| Sex: Female, Male(Participants) | BI 1584862 (R), Then BI 1584862 + Itraconazole (T) |
|---|---|
| Female | 0 |
| Male | 14 |
| Ethnicity (NIH/OMB)(Participants) | BI 1584862 (R), Then BI 1584862 + Itraconazole (T) |
|---|---|
| Hispanic or Latino | 0 |
| Not Hispanic or Latino | 14 |
| Unknown or Not Reported | 0 |
| Race (NIH/OMB)(Participants) | BI 1584862 (R), Then BI 1584862 + Itraconazole (T) |
|---|---|
| American Indian or Alaska Native | 0 |
| Asian | 0 |
| Native Hawaiian or Other Pacific Islander | 0 |
| Black or African American | 1 |
| White | 13 |
| More than one race | 0 |
| Unknown or Not Reported | 0 |
PDFs hosted by the registry, ClinicalTrials.gov.
Plan to share: No — Clinical studies sponsored by Boehringer Ingelheim, phases I to IV, interventional and non-interventional, are in scope for sharing of the raw clinical study data and clinical study documents. Exceptions might apply, e.g. studies in products where Boehringer Ingelheim is not the license holder; studies regarding pharmaceutical formulations and associated analytical methods, and studies pertinent to pharmacokinetics using human biomaterials; studies conducted in a single center or targeting rare diseases (in case of low number of patients and therefore limitations with anonymization). For more details refer to: https://www.mystudywindow.com/msw/datatransparency
Ran from Sep 2023 to primary completion in Nov 2023, 1 month.
Results were first posted in Jun 2026, 2 years 6 months after primary completion.
How these figures are worked out, and which studies are left out of them.
This study is completed, as verified in May 2026. You cannot join it, but the record below documents what was studied.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Studies of the drug tested here: BI 1584862